(11 May 2021) Thymosin alpha1a- significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025)
Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching https://doi.org/10.3389/fmed.2021.664776 Among 1,388 enrolled patients, 232 patients (16.7%) received both Thymosin-alpha1 therapy and standard therapy (Thymosin-alpha1 group), and 1,156 patients… Continue reading "(11 May 2021) Thymosin alpha1a- significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025)"